董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Richman | 男 | Director,President and Chief Executive Officer | 64 | 94.17万美元 | 22.14 | 2025-09-01 |
| David Kabakoff | 女 | Independent Director | 77 | 9.13万美元 | 1.96 | 2025-09-01 |
| Anne Borgman | 女 | Independent Director | 57 | 5.05万美元 | 0.87 | 2025-09-01 |
| John G. Houston | 男 | Independent Director | 65 | 5.65万美元 | 0.99 | 2025-09-01 |
| Ellen G. Feigal | 女 | Independent Director | 70 | 5.15万美元 | 0.87 | 2025-09-01 |
| Stephen W. Webster | 男 | Independent Director | 64 | 6.65万美元 | 0.97 | 2025-09-01 |
| Elaine V. Jones | 女 | Independent Director | 70 | 6.20万美元 | 0.97 | 2025-09-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Richman | 男 | Director,President and Chief Executive Officer | 64 | 94.17万美元 | 22.14 | 2025-09-01 |
| Steven P. Cobourn | 男 | Chief Financial Officer | 61 | 99.33万美元 | 未持股 | 2025-09-01 |
| Timothy Mayer | -- | Chief Operating Officer | 60 | 63.32万美元 | 7.11 | 2025-09-01 |
| Udayan Guha | 男 | Chief Medical Officer | 53 | 63.92万美元 | 1.68 | 2025-09-01 |
| Sourav Kundu | 男 | Senior Vice President, Development & Manufacturing | 65 | 未披露 | 未持股 | 2025-09-01 |
| Kevin G. Shaw | 男 | Senior Vice President, General Counsel | 51 | 未披露 | 未持股 | 2025-09-01 |
董事简历
中英对照 | 中文 | 英文- Michael Richman
-
Michael Richman于2015年4月被任命为公司董事。 Richman最先由Douglas J. Swirsky推荐位董事候选人。 Richman现任行业顾问。 Richman于2013年到2015年8月担任Amplimmune（AstraZeneca Group的一个成员）首席执行官。Amplimmune被AstraZeneca收购之前，他曾先后担任Amplimmune（当时是一家私营生物制品公司，专注于癌症和自身免疫性疾病）总裁、总裁和首席执行官的职位。2002年到2007年 Richman担任MacroGenics（一家临床阶段生物制药公司，专注于发现和开发治疗癌症、自身免疫性疾病和传染病的创新型单克隆抗体类疗法）执行副总裁和首席运营官。 Richman在研究、知识产权和业务发展能力方面有着30多年的丰富经验，包括Chiron Corporation（现名为Novartis ）以及MedImmune, Inc.。MedImmune, Inc.被AstraZeneca收购之前，他曾担任该公司企业开发高级副总裁。在 MedImmune任职期间， Richman负责所有的业务开发许可、知识产权法律事务、项目管理和战略规划职能部门，他还成功促进了很多次重要的交易。 Richman是 Opexa Therapeutics, Inc. Pieris Pharmaceuticals, Inc.（公共公司）以及 Madison Vaccines, Inc（私营公司）董事。他曾担任Cougar Biotechnology董事，直到该公司于2009年7月与Johnson & Johnson进行并购之后才停止任职。 Richman持有California大学达维斯分校遗传学和分子生物学理学学士学位；以及San Francisco State大学国际业务工商管理学硕士学位。
Michael Richman,served as President and Chief Executive Officer of Amplimmune, Inc. (now MedImmune, LLC), a biopharmaceutical company focused on immuno-oncology, from 2007 to August 2015, including through Amplimmune's acquisition by AstraZeneca plc in October 2013. Before Amplimmune, Mr. Richman served as Executive Vice President and Chief Operating Officer of MacroGenics, Inc., a biopharmaceutical company focused on the treatment of cancer, from 2002 to 2007. Mr. Richman joined MacroGenics with approximately 20 years' experience in corporate business development within the biotechnology industry. Mr. Richman was previously a member of the board of directors of GenVec, Inc. from April 2015 until its acquisition by Intrexon Corporation in June 2017, Opexa Therapeutics, Inc. from June 2006 until its acquisition by Acer Therapeutics in September 2017, Pieris Pharmaceuticals, Inc. from December 2014 until it merged with Palvella Therapeutics, Inc. in December 2024. He also served as a director of Madison Vaccines, Inc., a private company, from 2014 to 2024.Mr. Richman received a B.S. in genetics and molecular biology from the University of California at Davis and an M.S.B.A. in international business from San Francisco State University. - Michael Richman于2015年4月被任命为公司董事。 Richman最先由Douglas J. Swirsky推荐位董事候选人。 Richman现任行业顾问。 Richman于2013年到2015年8月担任Amplimmune（AstraZeneca Group的一个成员）首席执行官。Amplimmune被AstraZeneca收购之前，他曾先后担任Amplimmune（当时是一家私营生物制品公司，专注于癌症和自身免疫性疾病）总裁、总裁和首席执行官的职位。2002年到2007年 Richman担任MacroGenics（一家临床阶段生物制药公司，专注于发现和开发治疗癌症、自身免疫性疾病和传染病的创新型单克隆抗体类疗法）执行副总裁和首席运营官。 Richman在研究、知识产权和业务发展能力方面有着30多年的丰富经验，包括Chiron Corporation（现名为Novartis ）以及MedImmune, Inc.。MedImmune, Inc.被AstraZeneca收购之前，他曾担任该公司企业开发高级副总裁。在 MedImmune任职期间， Richman负责所有的业务开发许可、知识产权法律事务、项目管理和战略规划职能部门，他还成功促进了很多次重要的交易。 Richman是 Opexa Therapeutics, Inc. Pieris Pharmaceuticals, Inc.（公共公司）以及 Madison Vaccines, Inc（私营公司）董事。他曾担任Cougar Biotechnology董事，直到该公司于2009年7月与Johnson & Johnson进行并购之后才停止任职。 Richman持有California大学达维斯分校遗传学和分子生物学理学学士学位；以及San Francisco State大学国际业务工商管理学硕士学位。
- Michael Richman,served as President and Chief Executive Officer of Amplimmune, Inc. (now MedImmune, LLC), a biopharmaceutical company focused on immuno-oncology, from 2007 to August 2015, including through Amplimmune's acquisition by AstraZeneca plc in October 2013. Before Amplimmune, Mr. Richman served as Executive Vice President and Chief Operating Officer of MacroGenics, Inc., a biopharmaceutical company focused on the treatment of cancer, from 2002 to 2007. Mr. Richman joined MacroGenics with approximately 20 years' experience in corporate business development within the biotechnology industry. Mr. Richman was previously a member of the board of directors of GenVec, Inc. from April 2015 until its acquisition by Intrexon Corporation in June 2017, Opexa Therapeutics, Inc. from June 2006 until its acquisition by Acer Therapeutics in September 2017, Pieris Pharmaceuticals, Inc. from December 2014 until it merged with Palvella Therapeutics, Inc. in December 2024. He also served as a director of Madison Vaccines, Inc., a private company, from 2014 to 2024.Mr. Richman received a B.S. in genetics and molecular biology from the University of California at Davis and an M.S.B.A. in international business from San Francisco State University.
- David Kabakoff
-
David Kabakoff自2017年9月以来一直担任我们的董事会成员。自2012年以来，Kabakoff博士担任HealthQuest Capital的合伙人。自2007年以来，Kabakoff博士还担任Sofinnova Ventures的执行合伙人。Kabakoff博士目前担任NextCure，Inc.公司的董事会主席，该公司是一家公开上市的生物制药公司。Kabakoff博士还担任许多私人公司的董事会成员，包括生物制药公司Antiva Biosciences，Inc.，生物制药公司Daunless Pharmaceuticals，基因检测公司Lineagen董事长，分子诊断公司Biotheranostics，生物制药公司Rainier Therapeutics，Inc.和生物制药公司Neurana Pharmaceuticals，Inc.。从2006年到2014年10月，Kabakoff博士担任Intermune Inc.的董事，该公司是一家公开上市的生物制药公司。2001年，Kabakoff博士共同创立了SalMedix，Inc.，该公司是一家癌症药物治疗的开发商，曾担任其董事长兼首席执行官，并于2005年6月领导该公司被生物制药公司Cephalon，Inc.收购。从1996年到2000年，Kabakoff博士担任Dura Pharmaceuticals，Inc.的执行Vice President和Spiros的总裁兼首席执行官，这两家公司都是制药公司。Kabakoff从1989年到1996年担任Corvas International，Inc.（一家生物疗法开发商）首席执行官，从1983年到1989年担任Hybritech（一家生物技术公司）高级执行职位。Kabakoff博士拥有凯斯西储大学（Case Western Reserve University）的化学学士学位和耶鲁大学（Yale University）的博士学位。
David Kabakoff,has served as Executive Partner at Sofinnova Investments, Inc., a clinical-stage biopharmaceutical venture capital firm, since May 2007 and became a founding Partner of HealthQuest Capital, a health care innovation venture capital firm, in 2012. Dr. Kabakoff currently serves on the board of directors of the privately-held life sciences company RareCyte, Inc. Dr. Kabakoff previously served as a director of several other publicly traded and privately held life sciences companies, including Castle Biosciences, Inc. from September 2017 to August 2021, Principia Biopharma, Inc. from June 2016 to August 2018 in advance of Principia's September 2018 initial public offering, publicly traded lnterMune, Inc. from November 2005 to September 2014, and Amplimmune from 2007 until its acquisition by AstraZeneca plc in October 2013. In 2001, Dr. Kabakoff co-founded Salmedix, Inc., a company that developed cancer drug treatments, served as the company's Chairman and Chief Executive Officer and led its acquisition in June 2005 by Cephalon, Inc. Previously, Dr. Kabakoff served as Executive Vice President of Dura Pharmaceuticals, Inc., a pharmaceutical company, as President and Chief Executive Officer of Spiros, a pharmaceutical company, as Chief Executive Officer of Corvas International, Inc., a developer of biotherapeutics, and in senior executive positions with Hybritech, a biotechnology company. Dr. Kabakoff received a B.A. in chemistry from Case Western Reserve University and a Ph.D. in chemistry from Yale University. - David Kabakoff自2017年9月以来一直担任我们的董事会成员。自2012年以来，Kabakoff博士担任HealthQuest Capital的合伙人。自2007年以来，Kabakoff博士还担任Sofinnova Ventures的执行合伙人。Kabakoff博士目前担任NextCure，Inc.公司的董事会主席，该公司是一家公开上市的生物制药公司。Kabakoff博士还担任许多私人公司的董事会成员，包括生物制药公司Antiva Biosciences，Inc.，生物制药公司Daunless Pharmaceuticals，基因检测公司Lineagen董事长，分子诊断公司Biotheranostics，生物制药公司Rainier Therapeutics，Inc.和生物制药公司Neurana Pharmaceuticals，Inc.。从2006年到2014年10月，Kabakoff博士担任Intermune Inc.的董事，该公司是一家公开上市的生物制药公司。2001年，Kabakoff博士共同创立了SalMedix，Inc.，该公司是一家癌症药物治疗的开发商，曾担任其董事长兼首席执行官，并于2005年6月领导该公司被生物制药公司Cephalon，Inc.收购。从1996年到2000年，Kabakoff博士担任Dura Pharmaceuticals，Inc.的执行Vice President和Spiros的总裁兼首席执行官，这两家公司都是制药公司。Kabakoff从1989年到1996年担任Corvas International，Inc.（一家生物疗法开发商）首席执行官，从1983年到1989年担任Hybritech（一家生物技术公司）高级执行职位。Kabakoff博士拥有凯斯西储大学（Case Western Reserve University）的化学学士学位和耶鲁大学（Yale University）的博士学位。
- David Kabakoff,has served as Executive Partner at Sofinnova Investments, Inc., a clinical-stage biopharmaceutical venture capital firm, since May 2007 and became a founding Partner of HealthQuest Capital, a health care innovation venture capital firm, in 2012. Dr. Kabakoff currently serves on the board of directors of the privately-held life sciences company RareCyte, Inc. Dr. Kabakoff previously served as a director of several other publicly traded and privately held life sciences companies, including Castle Biosciences, Inc. from September 2017 to August 2021, Principia Biopharma, Inc. from June 2016 to August 2018 in advance of Principia's September 2018 initial public offering, publicly traded lnterMune, Inc. from November 2005 to September 2014, and Amplimmune from 2007 until its acquisition by AstraZeneca plc in October 2013. In 2001, Dr. Kabakoff co-founded Salmedix, Inc., a company that developed cancer drug treatments, served as the company's Chairman and Chief Executive Officer and led its acquisition in June 2005 by Cephalon, Inc. Previously, Dr. Kabakoff served as Executive Vice President of Dura Pharmaceuticals, Inc., a pharmaceutical company, as President and Chief Executive Officer of Spiros, a pharmaceutical company, as Chief Executive Officer of Corvas International, Inc., a developer of biotherapeutics, and in senior executive positions with Hybritech, a biotechnology company. Dr. Kabakoff received a B.A. in chemistry from Case Western Reserve University and a Ph.D. in chemistry from Yale University.
- Anne Borgman
-
Anne Borgman是一位经验丰富的肿瘤药物开发人员，最近于2023年2月起担任生物技术公司Sutro Biopharma, Inc.的首席医疗官，她将于2025年5月离职。在担任该职务之前，Borgman博士是AEB血液肿瘤学开发咨询公司的负责人，该职位于2021年11月至2023年2月担任，负责提供战略和战术/运营临床开发咨询。Borgman博士还曾于2019年至2021年担任全球生物制药公司爵士制药 PLC的血液学-肿瘤学副总裁兼全球治疗领域负责人。在加入爵士制药之前，她于2012年至2019年担任伊克力西斯 Biopharmaceuticals，Inc.的临床研发副总裁，此前曾在雅培担任全球治疗领域负责人肿瘤学，并担任湾区生物技术公司的首席医疗官。Dr。博格曼目前在Curis, Inc.（一家专注于开发治疗癌症的疗法的上市生物技术公司）和Nikang Therapeutics Inc.（一家专注于开发小分子肿瘤药物的私营临床阶段生物技术公司）担任董事会成员。博格曼博士完成了她在加州大学洛杉矶分校的临床和研究奖学金，儿科血液学肿瘤学和骨髓移植科，在此之前完成了她在贝勒医学院/德克萨斯儿童医院的儿科住院医师。博格曼博士在伊利诺伊大学获得生物化学理学学士学位，并在芝加哥洛约拉大学Stritch医学院获得医学博士学位。
Anne Borgman,is experienced developer of oncology drugs, and most recently served as the Chief Medical Officer of Sutro Biopharma, Inc., a biotechnology company, from February 2023, which role she will depart in May 2025. Before taking that role, Dr. Borgman was the Principal of AEB Hematology Oncology Development Consulting, a position held from November 2021 to February 2023, where she provided strategic and tactical/operational clinical development consulting. Dr. Borgman also served as Vice President and Global Therapeutic Area Lead, Hematology-Oncology of Jazz Pharmaceuticals plc, a global biopharmaceutical company, from 2019 to 2021.Prior to joining Jazz Pharmaceuticals, she served as Vice President, Clinical Research & Development at Exelixis Biopharmaceuticals, Inc. from 2012 to 2019, and has previously served as Global Therapeutic Area Head Oncology at Abbott Laboratories, and as Chief Medical Officer for biotech companies in the Bay Area.Dr. Borgman currently serves on the board of directors at Curis, Inc., a public biotechnology company focused on the development of therapeutics for the treatment of cancer, and NiKang Therapeutics Inc., a private clinical stage biotechnology company focused on developing small molecule oncology medicines. Dr. Borgman completed her clinical and research fellowship at the University of California, Los Angeles, Section of Pediatric Hematology Oncology and Bone Marrow Transplant, and prior to that completed her pediatric residency at Baylor College of Medicine/Texas Children's Hospital. Dr. Borgman received her Bachelor of Science in Biochemistry from the University of Illinois and received her M.D. from the Loyola University of Chicago Stritch School of Medicine. - Anne Borgman是一位经验丰富的肿瘤药物开发人员，最近于2023年2月起担任生物技术公司Sutro Biopharma, Inc.的首席医疗官，她将于2025年5月离职。在担任该职务之前，Borgman博士是AEB血液肿瘤学开发咨询公司的负责人，该职位于2021年11月至2023年2月担任，负责提供战略和战术/运营临床开发咨询。Borgman博士还曾于2019年至2021年担任全球生物制药公司爵士制药 PLC的血液学-肿瘤学副总裁兼全球治疗领域负责人。在加入爵士制药之前，她于2012年至2019年担任伊克力西斯 Biopharmaceuticals，Inc.的临床研发副总裁，此前曾在雅培担任全球治疗领域负责人肿瘤学，并担任湾区生物技术公司的首席医疗官。Dr。博格曼目前在Curis, Inc.（一家专注于开发治疗癌症的疗法的上市生物技术公司）和Nikang Therapeutics Inc.（一家专注于开发小分子肿瘤药物的私营临床阶段生物技术公司）担任董事会成员。博格曼博士完成了她在加州大学洛杉矶分校的临床和研究奖学金，儿科血液学肿瘤学和骨髓移植科，在此之前完成了她在贝勒医学院/德克萨斯儿童医院的儿科住院医师。博格曼博士在伊利诺伊大学获得生物化学理学学士学位，并在芝加哥洛约拉大学Stritch医学院获得医学博士学位。
- Anne Borgman,is experienced developer of oncology drugs, and most recently served as the Chief Medical Officer of Sutro Biopharma, Inc., a biotechnology company, from February 2023, which role she will depart in May 2025. Before taking that role, Dr. Borgman was the Principal of AEB Hematology Oncology Development Consulting, a position held from November 2021 to February 2023, where she provided strategic and tactical/operational clinical development consulting. Dr. Borgman also served as Vice President and Global Therapeutic Area Lead, Hematology-Oncology of Jazz Pharmaceuticals plc, a global biopharmaceutical company, from 2019 to 2021.Prior to joining Jazz Pharmaceuticals, she served as Vice President, Clinical Research & Development at Exelixis Biopharmaceuticals, Inc. from 2012 to 2019, and has previously served as Global Therapeutic Area Head Oncology at Abbott Laboratories, and as Chief Medical Officer for biotech companies in the Bay Area.Dr. Borgman currently serves on the board of directors at Curis, Inc., a public biotechnology company focused on the development of therapeutics for the treatment of cancer, and NiKang Therapeutics Inc., a private clinical stage biotechnology company focused on developing small molecule oncology medicines. Dr. Borgman completed her clinical and research fellowship at the University of California, Los Angeles, Section of Pediatric Hematology Oncology and Bone Marrow Transplant, and prior to that completed her pediatric residency at Baylor College of Medicine/Texas Children's Hospital. Dr. Borgman received her Bachelor of Science in Biochemistry from the University of Illinois and received her M.D. from the Loyola University of Chicago Stritch School of Medicine.
- John G. Houston
-
John G. Houston，曾担任临床阶段生物技术公司Arvinas Inc.的总裁兼首席执行官，并自2017年9月起担任其董事会成员。此前担任Arvinas研究发展部总裁、首席科学官，2017年1月至2017年9月。休斯顿博士目前还担任多家私营公司的董事，包括Oerth Bio LLC、Cybrexa，Inc.和Connecticut United for Research Excellence Inc（也称为BioCT）。在加入Arvinas之前，他在百时美施贵宝公司（“BMS”）工作了超过18年，担任的职责越来越多，并对所有Discovery Biology疾病团队以及各个Discovery技术部门负责。他于2015年9月至2016年8月担任BMS专业发现和研发场地开发高级副总裁，此前曾在BMS的发现生物学、应用生物技术和早期发现化学部门担任过多个职务。在BMS期间，Dr. Houston是BMS高级管理领导团队的成员，该团队审查并批准了200多个临床前候选药物，以进入早期开发阶段，其中一些已进入后期临床试验阶段，并走向商业化。他还是BMS“利用技术”计划的首席架构师和司机，该计划导致了行业领先的集成线索发现和优化过程。在加入BMS之前，他曾在英国Glaxo Welcome Research and Development工作，曾担任Lead Discovery Unit的负责人。休斯顿博士在格拉斯哥大学获得医学微生物学学士学位，在爱丁堡赫瑞瓦特大学获得微生物生物化学博士学位。
John G. Houston,has served as President and Chief Executive Officer of Arvinas Inc., a clinical-stage biotechnology company, and as a member of its board of directors since September 2017. He previously served as Arvnas' President of Research Development and Chief Scientific Officer from January 2017 to September 2017. Dr. Houston also currently serves as a director of several privately held companies, including Oerth Bio LLC, Cybrexa, Inc. and Connecticut United for Research Excellence Inc (also known as BioCT). Prior to joining Arvinas, he spent more than 18 years at Bristol Myers Squibb Company ("BMS") in roles of increasing responsibility and had accountability for all Discovery Biology disease teams, as well as various Discovery technology departments. He was the senior vice president of Specialty Discovery and R&D Site Development at BMS from September 2015 to August 2016 and previously worked in various roles across BMS' Discovery Biology, Applied Biotechnology and Early Discovery Chemistry departments. While at BMS Dr. Houston was a member of the BMS senior executive leadership team, which reviewed and approved over 200 pre-clinical candidates for progression into early development, several of which advanced into late-stage clinical trials, and toward commercialization. He was also the principal architect and driver of the "Leveraging Technology" initiative at BMS, which led to an industry- leading integrated lead discovery and optimization process. Prior to joining BMS, he worked at Glaxo Welcome Research and Development in the United Kingdom, where he served as head of the Lead Discovery Unit. Dr. Houston obtained a B.Sc. in Medical Microbiology from Glasgow University and a Ph.D. in Microbial Biochemistry from Heriot-Watt University, Edinburgh. - John G. Houston，曾担任临床阶段生物技术公司Arvinas Inc.的总裁兼首席执行官，并自2017年9月起担任其董事会成员。此前担任Arvinas研究发展部总裁、首席科学官，2017年1月至2017年9月。休斯顿博士目前还担任多家私营公司的董事，包括Oerth Bio LLC、Cybrexa，Inc.和Connecticut United for Research Excellence Inc（也称为BioCT）。在加入Arvinas之前，他在百时美施贵宝公司（“BMS”）工作了超过18年，担任的职责越来越多，并对所有Discovery Biology疾病团队以及各个Discovery技术部门负责。他于2015年9月至2016年8月担任BMS专业发现和研发场地开发高级副总裁，此前曾在BMS的发现生物学、应用生物技术和早期发现化学部门担任过多个职务。在BMS期间，Dr. Houston是BMS高级管理领导团队的成员，该团队审查并批准了200多个临床前候选药物，以进入早期开发阶段，其中一些已进入后期临床试验阶段，并走向商业化。他还是BMS“利用技术”计划的首席架构师和司机，该计划导致了行业领先的集成线索发现和优化过程。在加入BMS之前，他曾在英国Glaxo Welcome Research and Development工作，曾担任Lead Discovery Unit的负责人。休斯顿博士在格拉斯哥大学获得医学微生物学学士学位，在爱丁堡赫瑞瓦特大学获得微生物生物化学博士学位。
- John G. Houston,has served as President and Chief Executive Officer of Arvinas Inc., a clinical-stage biotechnology company, and as a member of its board of directors since September 2017. He previously served as Arvnas' President of Research Development and Chief Scientific Officer from January 2017 to September 2017. Dr. Houston also currently serves as a director of several privately held companies, including Oerth Bio LLC, Cybrexa, Inc. and Connecticut United for Research Excellence Inc (also known as BioCT). Prior to joining Arvinas, he spent more than 18 years at Bristol Myers Squibb Company ("BMS") in roles of increasing responsibility and had accountability for all Discovery Biology disease teams, as well as various Discovery technology departments. He was the senior vice president of Specialty Discovery and R&D Site Development at BMS from September 2015 to August 2016 and previously worked in various roles across BMS' Discovery Biology, Applied Biotechnology and Early Discovery Chemistry departments. While at BMS Dr. Houston was a member of the BMS senior executive leadership team, which reviewed and approved over 200 pre-clinical candidates for progression into early development, several of which advanced into late-stage clinical trials, and toward commercialization. He was also the principal architect and driver of the "Leveraging Technology" initiative at BMS, which led to an industry- leading integrated lead discovery and optimization process. Prior to joining BMS, he worked at Glaxo Welcome Research and Development in the United Kingdom, where he served as head of the Lead Discovery Unit. Dr. Houston obtained a B.Sc. in Medical Microbiology from Glasgow University and a Ph.D. in Microbial Biochemistry from Heriot-Watt University, Edinburgh.
- Ellen G. Feigal
-
Ellen G. Feigal，自2014年起担任NDA Partners LLC的合伙人兼生物制品业务负责人。NDA Partners是ProPharma Group的一部分，ProPharma Group是一家生命科学管理咨询和合同开发组织。Feigal博士目前还担任Xencor，Inc.和Prescient Therapeutics Ltd.的董事会成员。她目前还担任细胞和基因医学基金会的董事。Feigal博士曾担任美国国家癌症研究所癌症治疗/诊断司代理主任；加州再生医学研究所研发高级副总裁；安进全球发展执行医疗总监；Insys医疗首席医疗官；加州大学旧金山分校（UCSF）美国药物开发和监管科学课程的创始主任。在加入加州大学旧金山分校之前，Feigal博士是关键路径研究所的医疗设备和影像学主任，以及转化基因组学研究所的临床科学副总裁。Feigal博士在加州大学戴维斯分校获得医学博士学位，并在斯坦福大学完成了内科住院医师实习，在加州大学旧金山分校完成了血液学/肿瘤学研究金，目前担任亚利桑那州立大学Sandra Day O'Connor法学院的兼职教授。
Ellen G. Feigal,has served as a Partner and Head of the Biologics Practice at NDA Partners LLC since 2014. NDA Partners is part of ProPharma Group, a life sciences management consulting and contract development organization. Dr. Feigal also currently serves as a board member for Xencor, Inc. and Prescient Therapeutics Ltd. She also presently serves as a director for the Foundation for Cell and Gene Medicine. Dr. Feigal formerly served as Acting Director of the Division of Cancer Treatment/Diagnosis at the National Cancer Institute; Senior Vice President of Research and Development at the California Institute for Regenerative Medicine; Executive Medical Director, Global Development, at Amgen; Chief Medical Officer at Insys Therapeutics; and a Founding Director of the American Course on Drug Development and Regulatory Sciences at the University of California, San Francisco (UCSF). Prior to her position at UCSF, Dr. Feigal was Director of Medical Devices and Imaging at the Critical Path Institute and Vice President of Clinical Sciences at the Translational Genomics Research Institute. Dr. Feigal received her M.D. from the University of California, Davis and completed an internal medicine residency at Stanford University and a hematology/oncology fellowship at University of California, San Francisco, and currently serves as an adjunct professor at Arizona State University Sandra Day O'Connor College of Law. - Ellen G. Feigal，自2014年起担任NDA Partners LLC的合伙人兼生物制品业务负责人。NDA Partners是ProPharma Group的一部分，ProPharma Group是一家生命科学管理咨询和合同开发组织。Feigal博士目前还担任Xencor，Inc.和Prescient Therapeutics Ltd.的董事会成员。她目前还担任细胞和基因医学基金会的董事。Feigal博士曾担任美国国家癌症研究所癌症治疗/诊断司代理主任；加州再生医学研究所研发高级副总裁；安进全球发展执行医疗总监；Insys医疗首席医疗官；加州大学旧金山分校（UCSF）美国药物开发和监管科学课程的创始主任。在加入加州大学旧金山分校之前，Feigal博士是关键路径研究所的医疗设备和影像学主任，以及转化基因组学研究所的临床科学副总裁。Feigal博士在加州大学戴维斯分校获得医学博士学位，并在斯坦福大学完成了内科住院医师实习，在加州大学旧金山分校完成了血液学/肿瘤学研究金，目前担任亚利桑那州立大学Sandra Day O'Connor法学院的兼职教授。
- Ellen G. Feigal,has served as a Partner and Head of the Biologics Practice at NDA Partners LLC since 2014. NDA Partners is part of ProPharma Group, a life sciences management consulting and contract development organization. Dr. Feigal also currently serves as a board member for Xencor, Inc. and Prescient Therapeutics Ltd. She also presently serves as a director for the Foundation for Cell and Gene Medicine. Dr. Feigal formerly served as Acting Director of the Division of Cancer Treatment/Diagnosis at the National Cancer Institute; Senior Vice President of Research and Development at the California Institute for Regenerative Medicine; Executive Medical Director, Global Development, at Amgen; Chief Medical Officer at Insys Therapeutics; and a Founding Director of the American Course on Drug Development and Regulatory Sciences at the University of California, San Francisco (UCSF). Prior to her position at UCSF, Dr. Feigal was Director of Medical Devices and Imaging at the Critical Path Institute and Vice President of Clinical Sciences at the Translational Genomics Research Institute. Dr. Feigal received her M.D. from the University of California, Davis and completed an internal medicine residency at Stanford University and a hematology/oncology fellowship at University of California, San Francisco, and currently serves as an adjunct professor at Arizona State University Sandra Day O'Connor College of Law.
- Stephen W. Webster
-
Stephen W. Webster 于 2020 年 5 月加入 Tcr2 Therapeutics Inc. 董事会，并于 2022 年 1 月成为 Tcr2 Therapeutics Inc. 董事长。Webster 先生自 7 月起担任上市基因治疗生物技术公司 Spark Therapeutics 的首席财务官2014 年至 2019 年 12 月被罗氏以 48 亿美元收购。从 2012 年 7 月至 2013 年 10 月被 Cubist Pharmaceuticals 收购，他曾担任上市生物技术公司 Optimer Pharmaceuticals 的高级副总裁兼首席财务官。加入 Optimer 后，Webster 先生从 2008 年到 2011 年被 Cubist Pharmaceuticals 收购，担任生物制药公司 Adolor Corporation 的高级副总裁兼首席财务官。Webster 先生还曾在 Broadpoint Capital 的投资银行医疗保健集团和PaineWebber 公司。 Webster 先生自 2019 年 4 月起担任 NextCure 的董事，自 2016 年 8 月起担任 Nabriva Therapeutics AG（前身为 Nabriva Therapeutics plc），自 2020 年起担任 Cullinan Oncology, Inc. 的董事。Webster 先生获得了 A.B。达特茅斯学院经济学学士学位和宾夕法尼亚大学沃顿商学院金融学工商管理硕士学位。
Stephen W. Webster has served as a member of Eloxx Pharmaceuticals, Inc.'s board of directors since May 2026. Mr. Webster served as the Chief Financial Officer of Spark Therapeutics, Inc., a publicly traded biotechnology company, from July 2014 until its acquisition by the Roche Group in December 2019. He was previously Senior Vice President and Chief Financial Officer of Optimer Pharmaceuticals, Inc. ("Optimer"), a publicly traded biotechnology company, from July 2012 until its acquisition by Cubist Pharmaceuticals, Inc. ("Cubist") in October 2013. Prior to joining Optimer, Mr. Webster served as Senior Vice President and Chief Financial Officer of Adolor Corporation, a biopharmaceutical company, from 2008 until its acquisition by Cubist in 2011. From 2007 until joining Adolor Corporation in 2008, Mr. Webster served as Managing Director, Investment Banking Division, Health Care Group for Broadpoint Capital Inc. (formerly First Albany Capital). Mr. Webster served as co founder, President and Chief Executive Officer for Neuronyx, Inc., a biopharmaceutical company, from 2000 to 2006. Mr. Webster served in positions of increased responsibility, including as Director, Investment Banking Division, Health Care Group for PaineWebber Incorporated. Mr. Webster is currently a director of Cullinan Therapeutics (and a member of the audit, compensation and nominating and corporate governance committees) since September 2020 and NextCure Inc. (and a member of the audit and compensation committees) since April 2019. Previously, he has served as a director of Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc), a publicly traded biopharmaceutical company (June 2017 to December 2024) and TCR2 Therapeutics, a publicly traded biotherapeutics company (May 2020 to April 2023). Mr. Webster received an A.B. in economics from Dartmouth College and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania. - Stephen W. Webster 于 2020 年 5 月加入 Tcr2 Therapeutics Inc. 董事会，并于 2022 年 1 月成为 Tcr2 Therapeutics Inc. 董事长。Webster 先生自 7 月起担任上市基因治疗生物技术公司 Spark Therapeutics 的首席财务官2014 年至 2019 年 12 月被罗氏以 48 亿美元收购。从 2012 年 7 月至 2013 年 10 月被 Cubist Pharmaceuticals 收购，他曾担任上市生物技术公司 Optimer Pharmaceuticals 的高级副总裁兼首席财务官。加入 Optimer 后，Webster 先生从 2008 年到 2011 年被 Cubist Pharmaceuticals 收购，担任生物制药公司 Adolor Corporation 的高级副总裁兼首席财务官。Webster 先生还曾在 Broadpoint Capital 的投资银行医疗保健集团和PaineWebber 公司。 Webster 先生自 2019 年 4 月起担任 NextCure 的董事，自 2016 年 8 月起担任 Nabriva Therapeutics AG（前身为 Nabriva Therapeutics plc），自 2020 年起担任 Cullinan Oncology, Inc. 的董事。Webster 先生获得了 A.B。达特茅斯学院经济学学士学位和宾夕法尼亚大学沃顿商学院金融学工商管理硕士学位。
- Stephen W. Webster has served as a member of Eloxx Pharmaceuticals, Inc.'s board of directors since May 2026. Mr. Webster served as the Chief Financial Officer of Spark Therapeutics, Inc., a publicly traded biotechnology company, from July 2014 until its acquisition by the Roche Group in December 2019. He was previously Senior Vice President and Chief Financial Officer of Optimer Pharmaceuticals, Inc. ("Optimer"), a publicly traded biotechnology company, from July 2012 until its acquisition by Cubist Pharmaceuticals, Inc. ("Cubist") in October 2013. Prior to joining Optimer, Mr. Webster served as Senior Vice President and Chief Financial Officer of Adolor Corporation, a biopharmaceutical company, from 2008 until its acquisition by Cubist in 2011. From 2007 until joining Adolor Corporation in 2008, Mr. Webster served as Managing Director, Investment Banking Division, Health Care Group for Broadpoint Capital Inc. (formerly First Albany Capital). Mr. Webster served as co founder, President and Chief Executive Officer for Neuronyx, Inc., a biopharmaceutical company, from 2000 to 2006. Mr. Webster served in positions of increased responsibility, including as Director, Investment Banking Division, Health Care Group for PaineWebber Incorporated. Mr. Webster is currently a director of Cullinan Therapeutics (and a member of the audit, compensation and nominating and corporate governance committees) since September 2020 and NextCure Inc. (and a member of the audit and compensation committees) since April 2019. Previously, he has served as a director of Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc), a publicly traded biopharmaceutical company (June 2017 to December 2024) and TCR2 Therapeutics, a publicly traded biotherapeutics company (May 2020 to April 2023). Mr. Webster received an A.B. in economics from Dartmouth College and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania.
- Elaine V. Jones
-
Elaine V. Jones，于2008年12月至2019年4月在生命科学投资公司辉瑞 Ventures担任全球业务发展副总裁兼高级合伙人，负责进行和管理对辉瑞公司具有战略意义的风险投资。在加入辉瑞之前，Dr. Jones是EuclidSR Partners的普通合伙人。她于1999年在葛兰素史克的风险基金S.R. One开始了她的私募股权生涯。在此之前，她是SmithKline Beecham的科学许可总监，也是SmithKline Beecham Pharmaceutical R & D的研究科学家。Jones博士自2019年5月起担任上市的CytomX医疗，Inc.（一家临床阶段的生物制药公司）的董事会成员（她此前还曾在2014年12月至2016年6月期间担任CytomX的董事会成员），自2021年6月起担任医疗保健投资组合公司HBM Healthcare Investments Ltd.的董事会成员。她还于2021年2月至2023年3月担任Ibere Pharmaceuticals董事会成员，于2019年9月至2025年3月担任Gritsone Oncology，Inc.董事会成员。琼斯博士目前担任多家私营公司的董事会成员，包括Mironid Ltd.和Myeloid Therapeutics，Inc.，并担任Juniata College的受托人。Jones博士此前曾在多家公开上市的医疗保健公司的董事会任职，包括2015年2月至2018年6月的Mersana Therapeutics，2012年12月至2016年6月的Mirna Therapeutics，Inc.，2010年6月至2015年2月的Aquinox Pharmaceuticals，Inc.以及2009年12月至2014年6月的Flexion Therapeutics，Inc.。Jones博士在朱尼亚塔学院获得生物学学士学位，在匹兹堡大学获得微生物学博士学位。
Elaine V. Jones,served as Vice President, Worldwide Business Development and Senior Partner at Pfizer Ventures, a life sciences investment company, where she was responsible for making and managing venture investments of strategic interest to Pfizer Inc., from December 2008 to April 2019. Prior to joining Pfizer, Dr. Jones was a General Partner with EuclidSR Partners. She began her private equity career in 1999 at S.R. One, GlaxoSmithKline's venture fund. Before that, she was Director of Scientific Licensing for SmithKline Beecham and a research scientist for SmithKline Beecham Pharmaceutical R&D. Dr. Jones has served on the board of directors of publicly traded CytomX Therapeutics, Inc., a clinical-stage biopharmaceutical company, since May 2019 (she also previously served on CytomX's board from December 2014 to June 2016), and HBM Healthcare Investments Ltd., a healthcare investment portfolio company, since June 2021. She also served on the board of Ibere Pharmaceuticals from February 2021 to March 2023, and Gritsone Oncology, Inc. from September 2019 to March 2025. Dr. Jones currently serves on the board of directors for various privately held companies, including Mironid Ltd. and Myeloid Therapeutics, Inc., and as a trustee of Juniata College. Dr. Jones previously served on the boards of directors of several publicly traded healthcare companies, including Mersana Therapeutics, Inc. from February 2015 to June 2018, Mirna Therapeutics, Inc. from December 2012 to June 2016, Aquinox Pharmaceuticals, Inc. from June 2010 to February 2015 and Flexion Therapeutics, Inc. from December 2009 to June 2014. Dr. Jones received a B.S. in biology from Juniata College and a Ph.D. in microbiology from the University of Pittsburgh. - Elaine V. Jones，于2008年12月至2019年4月在生命科学投资公司辉瑞 Ventures担任全球业务发展副总裁兼高级合伙人，负责进行和管理对辉瑞公司具有战略意义的风险投资。在加入辉瑞之前，Dr. Jones是EuclidSR Partners的普通合伙人。她于1999年在葛兰素史克的风险基金S.R. One开始了她的私募股权生涯。在此之前，她是SmithKline Beecham的科学许可总监，也是SmithKline Beecham Pharmaceutical R & D的研究科学家。Jones博士自2019年5月起担任上市的CytomX医疗，Inc.（一家临床阶段的生物制药公司）的董事会成员（她此前还曾在2014年12月至2016年6月期间担任CytomX的董事会成员），自2021年6月起担任医疗保健投资组合公司HBM Healthcare Investments Ltd.的董事会成员。她还于2021年2月至2023年3月担任Ibere Pharmaceuticals董事会成员，于2019年9月至2025年3月担任Gritsone Oncology，Inc.董事会成员。琼斯博士目前担任多家私营公司的董事会成员，包括Mironid Ltd.和Myeloid Therapeutics，Inc.，并担任Juniata College的受托人。Jones博士此前曾在多家公开上市的医疗保健公司的董事会任职，包括2015年2月至2018年6月的Mersana Therapeutics，2012年12月至2016年6月的Mirna Therapeutics，Inc.，2010年6月至2015年2月的Aquinox Pharmaceuticals，Inc.以及2009年12月至2014年6月的Flexion Therapeutics，Inc.。Jones博士在朱尼亚塔学院获得生物学学士学位，在匹兹堡大学获得微生物学博士学位。
- Elaine V. Jones,served as Vice President, Worldwide Business Development and Senior Partner at Pfizer Ventures, a life sciences investment company, where she was responsible for making and managing venture investments of strategic interest to Pfizer Inc., from December 2008 to April 2019. Prior to joining Pfizer, Dr. Jones was a General Partner with EuclidSR Partners. She began her private equity career in 1999 at S.R. One, GlaxoSmithKline's venture fund. Before that, she was Director of Scientific Licensing for SmithKline Beecham and a research scientist for SmithKline Beecham Pharmaceutical R&D. Dr. Jones has served on the board of directors of publicly traded CytomX Therapeutics, Inc., a clinical-stage biopharmaceutical company, since May 2019 (she also previously served on CytomX's board from December 2014 to June 2016), and HBM Healthcare Investments Ltd., a healthcare investment portfolio company, since June 2021. She also served on the board of Ibere Pharmaceuticals from February 2021 to March 2023, and Gritsone Oncology, Inc. from September 2019 to March 2025. Dr. Jones currently serves on the board of directors for various privately held companies, including Mironid Ltd. and Myeloid Therapeutics, Inc., and as a trustee of Juniata College. Dr. Jones previously served on the boards of directors of several publicly traded healthcare companies, including Mersana Therapeutics, Inc. from February 2015 to June 2018, Mirna Therapeutics, Inc. from December 2012 to June 2016, Aquinox Pharmaceuticals, Inc. from June 2010 to February 2015 and Flexion Therapeutics, Inc. from December 2009 to June 2014. Dr. Jones received a B.S. in biology from Juniata College and a Ph.D. in microbiology from the University of Pittsburgh.
高管简历
中英对照 | 中文 | 英文- Michael Richman
Michael Richman于2015年4月被任命为公司董事。 Richman最先由Douglas J. Swirsky推荐位董事候选人。 Richman现任行业顾问。 Richman于2013年到2015年8月担任Amplimmune（AstraZeneca Group的一个成员）首席执行官。Amplimmune被AstraZeneca收购之前，他曾先后担任Amplimmune（当时是一家私营生物制品公司，专注于癌症和自身免疫性疾病）总裁、总裁和首席执行官的职位。2002年到2007年 Richman担任MacroGenics（一家临床阶段生物制药公司，专注于发现和开发治疗癌症、自身免疫性疾病和传染病的创新型单克隆抗体类疗法）执行副总裁和首席运营官。 Richman在研究、知识产权和业务发展能力方面有着30多年的丰富经验，包括Chiron Corporation（现名为Novartis ）以及MedImmune, Inc.。MedImmune, Inc.被AstraZeneca收购之前，他曾担任该公司企业开发高级副总裁。在 MedImmune任职期间， Richman负责所有的业务开发许可、知识产权法律事务、项目管理和战略规划职能部门，他还成功促进了很多次重要的交易。 Richman是 Opexa Therapeutics, Inc. Pieris Pharmaceuticals, Inc.（公共公司）以及 Madison Vaccines, Inc（私营公司）董事。他曾担任Cougar Biotechnology董事，直到该公司于2009年7月与Johnson & Johnson进行并购之后才停止任职。 Richman持有California大学达维斯分校遗传学和分子生物学理学学士学位；以及San Francisco State大学国际业务工商管理学硕士学位。
Michael Richman,served as President and Chief Executive Officer of Amplimmune, Inc. (now MedImmune, LLC), a biopharmaceutical company focused on immuno-oncology, from 2007 to August 2015, including through Amplimmune's acquisition by AstraZeneca plc in October 2013. Before Amplimmune, Mr. Richman served as Executive Vice President and Chief Operating Officer of MacroGenics, Inc., a biopharmaceutical company focused on the treatment of cancer, from 2002 to 2007. Mr. Richman joined MacroGenics with approximately 20 years' experience in corporate business development within the biotechnology industry. Mr. Richman was previously a member of the board of directors of GenVec, Inc. from April 2015 until its acquisition by Intrexon Corporation in June 2017, Opexa Therapeutics, Inc. from June 2006 until its acquisition by Acer Therapeutics in September 2017, Pieris Pharmaceuticals, Inc. from December 2014 until it merged with Palvella Therapeutics, Inc. in December 2024. He also served as a director of Madison Vaccines, Inc., a private company, from 2014 to 2024.Mr. Richman received a B.S. in genetics and molecular biology from the University of California at Davis and an M.S.B.A. in international business from San Francisco State University.- Michael Richman于2015年4月被任命为公司董事。 Richman最先由Douglas J. Swirsky推荐位董事候选人。 Richman现任行业顾问。 Richman于2013年到2015年8月担任Amplimmune（AstraZeneca Group的一个成员）首席执行官。Amplimmune被AstraZeneca收购之前，他曾先后担任Amplimmune（当时是一家私营生物制品公司，专注于癌症和自身免疫性疾病）总裁、总裁和首席执行官的职位。2002年到2007年 Richman担任MacroGenics（一家临床阶段生物制药公司，专注于发现和开发治疗癌症、自身免疫性疾病和传染病的创新型单克隆抗体类疗法）执行副总裁和首席运营官。 Richman在研究、知识产权和业务发展能力方面有着30多年的丰富经验，包括Chiron Corporation（现名为Novartis ）以及MedImmune, Inc.。MedImmune, Inc.被AstraZeneca收购之前，他曾担任该公司企业开发高级副总裁。在 MedImmune任职期间， Richman负责所有的业务开发许可、知识产权法律事务、项目管理和战略规划职能部门，他还成功促进了很多次重要的交易。 Richman是 Opexa Therapeutics, Inc. Pieris Pharmaceuticals, Inc.（公共公司）以及 Madison Vaccines, Inc（私营公司）董事。他曾担任Cougar Biotechnology董事，直到该公司于2009年7月与Johnson & Johnson进行并购之后才停止任职。 Richman持有California大学达维斯分校遗传学和分子生物学理学学士学位；以及San Francisco State大学国际业务工商管理学硕士学位。
- Michael Richman,served as President and Chief Executive Officer of Amplimmune, Inc. (now MedImmune, LLC), a biopharmaceutical company focused on immuno-oncology, from 2007 to August 2015, including through Amplimmune's acquisition by AstraZeneca plc in October 2013. Before Amplimmune, Mr. Richman served as Executive Vice President and Chief Operating Officer of MacroGenics, Inc., a biopharmaceutical company focused on the treatment of cancer, from 2002 to 2007. Mr. Richman joined MacroGenics with approximately 20 years' experience in corporate business development within the biotechnology industry. Mr. Richman was previously a member of the board of directors of GenVec, Inc. from April 2015 until its acquisition by Intrexon Corporation in June 2017, Opexa Therapeutics, Inc. from June 2006 until its acquisition by Acer Therapeutics in September 2017, Pieris Pharmaceuticals, Inc. from December 2014 until it merged with Palvella Therapeutics, Inc. in December 2024. He also served as a director of Madison Vaccines, Inc., a private company, from 2014 to 2024.Mr. Richman received a B.S. in genetics and molecular biology from the University of California at Davis and an M.S.B.A. in international business from San Francisco State University.
- Steven P. Cobourn
StevenP.Cobourn自2018年1月起担任我们的首席财务官。此前，他曾于2014年5月至2018年1月担任生物技术公司Vaccinex，Inc.的首席财务官。在加入Vaccinex之前，Cobourn先生于2003年至2014年4月担任私人制药公司Otsuka America Pharmaceutical，Inc.的财务Vice President兼财务主管，并于1993年至2003年在Otsuka America Pharmaceutical担任其他职务。在加入Otsuka America Pharmaceutical之前，Cobourn先生是Hass&Company LLC的注册会计师，这是一家会计师事务所。Cobourn先生在德雷克塞尔大学（Drexel University）获得工商管理学士学位，是一名注册会计师。
Steven P. Cobourn,served as Chief Financial Officer of Vaccinex, Inc., a biotechnology company, from May 2014 to January 2018. Prior to joining Vaccinex, Mr. Cobourn was the Vice President of Finance and Treasurer of Otsuka America Pharmaceutical, Inc., a private pharmaceutical company, from 2003 to April 2014, and served in other roles at Otsuka America Pharmaceutical from 1993 to 2003. Prior to joining Otsuka America Pharmaceutical, Mr. Cobourn was a Certified Public Accountant at Hass & Company LLC, an accounting firm. Mr. Cobourn received a B.S. in business administration from Drexel University and is a Certified Public Accountant.- StevenP.Cobourn自2018年1月起担任我们的首席财务官。此前，他曾于2014年5月至2018年1月担任生物技术公司Vaccinex，Inc.的首席财务官。在加入Vaccinex之前，Cobourn先生于2003年至2014年4月担任私人制药公司Otsuka America Pharmaceutical，Inc.的财务Vice President兼财务主管，并于1993年至2003年在Otsuka America Pharmaceutical担任其他职务。在加入Otsuka America Pharmaceutical之前，Cobourn先生是Hass&Company LLC的注册会计师，这是一家会计师事务所。Cobourn先生在德雷克塞尔大学（Drexel University）获得工商管理学士学位，是一名注册会计师。
- Steven P. Cobourn,served as Chief Financial Officer of Vaccinex, Inc., a biotechnology company, from May 2014 to January 2018. Prior to joining Vaccinex, Mr. Cobourn was the Vice President of Finance and Treasurer of Otsuka America Pharmaceutical, Inc., a private pharmaceutical company, from 2003 to April 2014, and served in other roles at Otsuka America Pharmaceutical from 1993 to 2003. Prior to joining Otsuka America Pharmaceutical, Mr. Cobourn was a Certified Public Accountant at Hass & Company LLC, an accounting firm. Mr. Cobourn received a B.S. in business administration from Drexel University and is a Certified Public Accountant.
- Timothy Mayer
Timothy Mayer自2018年12月以来一直担任我们的高级副总裁，企业发展，此前曾于2016年2月至2018年12月担任我们的业务发展Vice President。在加入NextCure之前，Mayer博士曾于2004年至2016年2月在专注于癌症治疗的生物制药公司Macrogenics，Inc.担任过多个职位，包括2009年至2016年2月担任知识产权高级总监。在此之前，Mayer博士从2000年到2004年在Banner&Witcoff，Ltd.（一家知识产权律师事务所）担任技术专家，负责生物技术和制药专利事务。Mayer博士在加州理工大学（California Polytechnic State University）获得微生物学学士学位和生物化学学士学位，并在宾夕法尼亚州立大学医学院（Pennsylvania State University College of Medicine）获得微生物学和免疫学博士学位。
Timothy Mayer,held several positions at MacroGenics, Inc., a biopharmaceutical company focused on the treatment of cancer, from 2004 to February 2016, including Senior Director, Intellectual Property from 2009 to February 2016. Prior to that, Dr. Mayer worked on biotechnology and pharmaceutical patent matters as a Technical Specialist at Banner & Witcoff, Ltd., an intellectual property law firm, from 2000 to 2004. Dr. Mayer received a B.S. in microbiology and a B.S. in biochemistry from California Polytechnic State University and a Ph.D. in microbiology and immunology from the Pennsylvania State University College of Medicine.- Timothy Mayer自2018年12月以来一直担任我们的高级副总裁，企业发展，此前曾于2016年2月至2018年12月担任我们的业务发展Vice President。在加入NextCure之前，Mayer博士曾于2004年至2016年2月在专注于癌症治疗的生物制药公司Macrogenics，Inc.担任过多个职位，包括2009年至2016年2月担任知识产权高级总监。在此之前，Mayer博士从2000年到2004年在Banner&Witcoff，Ltd.（一家知识产权律师事务所）担任技术专家，负责生物技术和制药专利事务。Mayer博士在加州理工大学（California Polytechnic State University）获得微生物学学士学位和生物化学学士学位，并在宾夕法尼亚州立大学医学院（Pennsylvania State University College of Medicine）获得微生物学和免疫学博士学位。
- Timothy Mayer,held several positions at MacroGenics, Inc., a biopharmaceutical company focused on the treatment of cancer, from 2004 to February 2016, including Senior Director, Intellectual Property from 2009 to February 2016. Prior to that, Dr. Mayer worked on biotechnology and pharmaceutical patent matters as a Technical Specialist at Banner & Witcoff, Ltd., an intellectual property law firm, from 2000 to 2004. Dr. Mayer received a B.S. in microbiology and a B.S. in biochemistry from California Polytechnic State University and a Ph.D. in microbiology and immunology from the Pennsylvania State University College of Medicine.
- Udayan Guha
Udayan Guha，是一名内科科学家，在靶向治疗、免疫治疗和细胞治疗方面拥有超过15年的学术、制药和生物技术之间的临床开发经验。在加入NextCure之前，他是TCR2 Therapeutics的副总裁兼临床开发负责人，现在是Adaptimmune的一部分。在加入TCR2 Therapeutics之前，Guha博士曾在Bristol Myers Squibb担任多项first-in-class first-in-human immunotherapy研究的临床负责人，从事早期临床开发工作。在加入制药和生物技术公司之前，Guha博士作为美国国家癌症研究所（NCI）、美国国立卫生研究院（NIH）、马里兰州贝塞斯达的研究员，在学术界有着非常富有成效的职业生涯，在那里他领导了一项肺癌靶向治疗的板凳到床边和背部项目。他的实验室研究重点是了解肿瘤异质性和对表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）耐药的机制Nextcure，Inc.基于质谱的蛋白质组学、NGS测序和小鼠建模。他还发起了几项由研究者发起的临床研究，包括首个住院临终关怀和快速/温热尸检研究，以在美国国立卫生研究院临床中心询问肿瘤异质性的机制。Guha博士毕业于印度北德里全印度医学科学研究所（AIIMS），获得MBBS学位，随后在纽约州布朗克斯的阿尔伯特·爱因斯坦医学院获得神经科学博士学位。随后，他在雅各比医学中心做了内科住院医师，并在纪念斯隆-凯特琳癌症中心（MESKCC）做了肿瘤学研究金，期间他还在诺贝尔奖获得者哈罗德·瓦姆斯博士的实验室做了博士后研究。
Udayan Guha,is a physician scientist with more than 15 years of clinical development experience between academia, pharma, and biotech in targeted therapy, immunotherapy, and cellular therapy. Before joining NextCure, he was VP, Head of Clinical Development at TCR2 Therapeutics, now part of Adaptimmune. Prior to TCR2 Therapeutics, Dr. Guha worked in Early Clinical Development as the Clinical Lead for several first-in-class first-in-human immunotherapy studies at Bristol Myers Squibb. Prior to joining pharma and biotech, Dr. Guha had a very productive career in academia as an Investigator at the National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD where he led a bench-to-bedside-and-back program in targeted therapy in lung cancer. His laboratory research was focused on understanding tumor heterogeneity and mechanisms of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) Nextcure, Inc. ing mass spectrometry-based proteomics, NGS sequencing, and mouse modeling. He also initiated several investigator-initiated clinical studies, including the first in-patient hospice and rapid/warm autopsy study to interrogate mechanisms of tumor heterogeneity at the NIH Clinical Center. Dr. Guha graduated from All India Institute of Medical Sciences (AIIMS), N. Delhi, India with an MBBS degree followed by a Ph.D. in Neuroscience at Albert Einstein College of Medicine, Bronx, NY. Subsequently, he did his Internal Medicine residency at Jacobi Medical Center and an Oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC) during which he also did postdoctoral research in the laboratory of Nobel Laureate, Dr. Harold Varmus.- Udayan Guha，是一名内科科学家，在靶向治疗、免疫治疗和细胞治疗方面拥有超过15年的学术、制药和生物技术之间的临床开发经验。在加入NextCure之前，他是TCR2 Therapeutics的副总裁兼临床开发负责人，现在是Adaptimmune的一部分。在加入TCR2 Therapeutics之前，Guha博士曾在Bristol Myers Squibb担任多项first-in-class first-in-human immunotherapy研究的临床负责人，从事早期临床开发工作。在加入制药和生物技术公司之前，Guha博士作为美国国家癌症研究所（NCI）、美国国立卫生研究院（NIH）、马里兰州贝塞斯达的研究员，在学术界有着非常富有成效的职业生涯，在那里他领导了一项肺癌靶向治疗的板凳到床边和背部项目。他的实验室研究重点是了解肿瘤异质性和对表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）耐药的机制Nextcure，Inc.基于质谱的蛋白质组学、NGS测序和小鼠建模。他还发起了几项由研究者发起的临床研究，包括首个住院临终关怀和快速/温热尸检研究，以在美国国立卫生研究院临床中心询问肿瘤异质性的机制。Guha博士毕业于印度北德里全印度医学科学研究所（AIIMS），获得MBBS学位，随后在纽约州布朗克斯的阿尔伯特·爱因斯坦医学院获得神经科学博士学位。随后，他在雅各比医学中心做了内科住院医师，并在纪念斯隆-凯特琳癌症中心（MESKCC）做了肿瘤学研究金，期间他还在诺贝尔奖获得者哈罗德·瓦姆斯博士的实验室做了博士后研究。
- Udayan Guha,is a physician scientist with more than 15 years of clinical development experience between academia, pharma, and biotech in targeted therapy, immunotherapy, and cellular therapy. Before joining NextCure, he was VP, Head of Clinical Development at TCR2 Therapeutics, now part of Adaptimmune. Prior to TCR2 Therapeutics, Dr. Guha worked in Early Clinical Development as the Clinical Lead for several first-in-class first-in-human immunotherapy studies at Bristol Myers Squibb. Prior to joining pharma and biotech, Dr. Guha had a very productive career in academia as an Investigator at the National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD where he led a bench-to-bedside-and-back program in targeted therapy in lung cancer. His laboratory research was focused on understanding tumor heterogeneity and mechanisms of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) Nextcure, Inc. ing mass spectrometry-based proteomics, NGS sequencing, and mouse modeling. He also initiated several investigator-initiated clinical studies, including the first in-patient hospice and rapid/warm autopsy study to interrogate mechanisms of tumor heterogeneity at the NIH Clinical Center. Dr. Guha graduated from All India Institute of Medical Sciences (AIIMS), N. Delhi, India with an MBBS degree followed by a Ph.D. in Neuroscience at Albert Einstein College of Medicine, Bronx, NY. Subsequently, he did his Internal Medicine residency at Jacobi Medical Center and an Oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC) during which he also did postdoctoral research in the laboratory of Nobel Laureate, Dr. Harold Varmus.
- Sourav Kundu
Sourav Kundu，2012年至2021年在梯瓦制药担任生物制剂研发— CMC副总裁。2004年至2012年在安进担任工艺开发总监。在此之前，Kundu博士曾于1998年至2004年在Aventis Behring担任高级经理。昆都博士获得韦恩州立大学化学工程学硕士和博士学位。昆杜博士在底特律医学中心和韦恩州立大学医学院进行博士后培训。
Sourav Kundu,served as Vice President of Biologics R&D—CMC at Teva Pharmaceuticals from 2012 to 2021. He served as Director, Process Development at Amgen from 2004 to 2012. Prior to this, Dr. Kundu served as a Senior Manager at Aventis Behring from 1998 to 2004. Dr. Kundu received an M.S. and a Ph.D. in Chemical Engineering from Wayne State University. Dr. Kundu conducted his postdoctoral training at the Detroit Medical Center and Wayne State University School of Medicine.- Sourav Kundu，2012年至2021年在梯瓦制药担任生物制剂研发— CMC副总裁。2004年至2012年在安进担任工艺开发总监。在此之前，Kundu博士曾于1998年至2004年在Aventis Behring担任高级经理。昆都博士获得韦恩州立大学化学工程学硕士和博士学位。昆杜博士在底特律医学中心和韦恩州立大学医学院进行博士后培训。
- Sourav Kundu,served as Vice President of Biologics R&D—CMC at Teva Pharmaceuticals from 2012 to 2021. He served as Director, Process Development at Amgen from 2004 to 2012. Prior to this, Dr. Kundu served as a Senior Manager at Aventis Behring from 1998 to 2004. Dr. Kundu received an M.S. and a Ph.D. in Chemical Engineering from Wayne State University. Dr. Kundu conducted his postdoctoral training at the Detroit Medical Center and Wayne State University School of Medicine.
- Kevin G. Shaw
Kevin G. Shaw，曾在Precigen, Inc.担任副总裁兼副总法律顾问，该公司是一家上市的生物技术和临床阶段细胞和基因治疗公司（之前称为Intrexon Corporation），他于2012年1月加入该公司。此前，Shaw先生曾于2000年至2011年12月在跨国律师事务所Hogan Lovells从事法律业务，在那里他代表大型和小型生命科学公司处理一系列知识产权和交易事务。肖先生在乔治华盛顿大学法学院获得法学博士学位，并在宾夕法尼亚大学获得化学工程本科学位。
Kevin G. Shaw,served as Vice President and Deputy General Counsel at Precigen, Inc., a publicly traded biotechnology and clinical stage cell and gene therapy company (previously known as Intrexon Corporation), which he joined in January 2012. Previously, Mr. Shaw practiced law at the multinational law firm Hogan Lovells from 2000 until December 2011, where he represented both large and small life sciences companies in a range of intellectual property and transactional matters. Mr. Shaw received his juris doctor from the George Washington University Law School and his undergraduate engineering degree in chemical engineering from the University of Pennsylvania.- Kevin G. Shaw，曾在Precigen, Inc.担任副总裁兼副总法律顾问，该公司是一家上市的生物技术和临床阶段细胞和基因治疗公司（之前称为Intrexon Corporation），他于2012年1月加入该公司。此前，Shaw先生曾于2000年至2011年12月在跨国律师事务所Hogan Lovells从事法律业务，在那里他代表大型和小型生命科学公司处理一系列知识产权和交易事务。肖先生在乔治华盛顿大学法学院获得法学博士学位，并在宾夕法尼亚大学获得化学工程本科学位。
- Kevin G. Shaw,served as Vice President and Deputy General Counsel at Precigen, Inc., a publicly traded biotechnology and clinical stage cell and gene therapy company (previously known as Intrexon Corporation), which he joined in January 2012. Previously, Mr. Shaw practiced law at the multinational law firm Hogan Lovells from 2000 until December 2011, where he represented both large and small life sciences companies in a range of intellectual property and transactional matters. Mr. Shaw received his juris doctor from the George Washington University Law School and his undergraduate engineering degree in chemical engineering from the University of Pennsylvania.